18,841 Illumina, Inc. $ILMN Shares Bought by ProShare Advisors LLC

ProShare Advisors LLC lifted its position in Illumina, Inc. (NASDAQ:ILMN) by 165.8% during the third quarter, Holdings Channel reports. The institutional investor owned 30,204 shares of the life sciences company’s stock after buying an additional 18,841 shares during the quarter. ProShare Advisors LLC’s holdings in Illumina were worth $8,266,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Baker Tilly Wealth Management LLC boosted its stake in Illumina by 3.3% during the third quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock valued at $355,000 after buying an additional 42 shares in the last quarter. Ashton Thomas Securities LLC grew its holdings in Illumina by 3.3% during the third quarter. Ashton Thomas Securities LLC now owns 1,348 shares of the life sciences company’s stock worth $369,000 after acquiring an additional 43 shares during the period. Elevation Wealth Partners LLC raised its position in Illumina by 19.7% in the third quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company’s stock worth $80,000 after acquiring an additional 48 shares in the last quarter. Evergreen Capital Management LLC raised its position in Illumina by 0.5% in the third quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company’s stock worth $2,593,000 after acquiring an additional 50 shares in the last quarter. Finally, Pinnacle Associates Ltd. lifted its holdings in Illumina by 2.2% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,506 shares of the life sciences company’s stock valued at $686,000 after acquiring an additional 54 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 4.9%

Shares of Illumina stock opened at $226.54 on Thursday. The stock’s fifty day moving average is $249.77 and its 200-day moving average is $177.46. The firm has a market capitalization of $34.25 billion, a PE ratio of 38.99, a price-to-earnings-growth ratio of 3.23 and a beta of 1.46. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. Illumina, Inc. has a 12-month low of $112.65 and a 12-month high of $309.35.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The business had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the prior year, the business posted $1.34 earnings per share. Illumina’s revenue was up 4.2% compared to the same quarter last year. Equities analysts anticipate that Illumina, Inc. will post 5.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of several research reports. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. Guggenheim boosted their target price on shares of Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Argus boosted their target price on shares of Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Stephens lowered shares of Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 target price for the company. in a research note on Friday, October 23rd. Finally, TD Cowen raised their target price on shares of Illumina from $210.00 to $270.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $244.24.

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 299,336 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the sale, the director owned 1,409,851 shares in the company, valued at approximately $307,291,123.96. The trade was a 17.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,320,108 shares of company stock worth $288,195,392 in the last three months. 2.90% of the stock is currently owned by company insiders.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina was selected to provide whole-genome sequencing for Singapore’s SG-INSIGHT study, part of the country’s National Precision Medicine program. The study aims to include about 450,000 people, expanding Illumina’s role in a large public-health genomics initiative. The announcement did not disclose contract value or expected revenue, so the immediate financial contribution is unclear. Article: Illumina selected to help bring precision medicine into everyday healthcare in Singapore
• Positive Sentiment: Citigroup raised its price target for Illumina, signaling a more favorable valuation view from the analyst. The available report does not specify the revised target or rationale. Article: Illumina stock gets price target boost from Citigroup
• Neutral Sentiment: Grail reported weaker-than-expected sales of its cancer-detection blood test, sending Grail shares lower. This is not a direct Illumina operating result; any impact on ILMN would be indirect sentiment or read-through, rather than evidence of weaker Illumina sales. Article: Grail Comes Up Short, Reporting Light Sales Of Its Cancer-Detecting Blood Test

Illumina Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.